The Experts below are selected from a list of 318 Experts worldwide ranked by ideXlab platform

Jin Mo Yang - One of the best experts on this subject based on the ideXlab platform.

Myeong Jun Song - One of the best experts on this subject based on the ideXlab platform.

Do Seon Song - One of the best experts on this subject based on the ideXlab platform.

Nancy E. Kemeny - One of the best experts on this subject based on the ideXlab platform.

  • treatment options in colorectal liver metastases Hepatic Arterial Infusion
    Visceral medicine, 2017
    Co-Authors: Alice Zervoudakis, Taryn M Boucher, Nancy E. Kemeny
    Abstract:

    Background: The liver is the most common site for metastases from colorectal cancer (CRC) with the majority of these patients having unresectable disease. Methods: This is a retrospective review of studies using Hepatic Arterial Infusion (HAI) therapy to treat liver metastasis from CRC. A PubMed search of randomized controlled trials and retrospective studies from 2006 to present was conducted using the search terms ‘Hepatic Arterial Infusion (HAI) therapy', ‘colorectal cancer', and ‘treatment of liver metastases'. Results: The first randomized studies comparing HAI to systemic therapy with 5-fluorouracil/leucovorin produced significantly higher response rates of 41 versus 14%. Systemic therapy has improved with the addition of irinotecan and oxaliplatin; however, the responses with HAI and these modern agents have also increased, with responses as high as 80%. For patients with wild-type KRAS, HAI and systemic therapy produced a median survival of 68 months. In patients with refractory disease, response rates are in the 30% range with a median survival of 20 months. Adjuvant HAI after liver resection has shown an increase of Hepatic disease-free survival and overall disease-free survival when compared to systemic therapy alone in three of four randomized trials. A recent update of the adjuvant trials after liver resection at Memorial Sloan Kettering Cancer Center has shown a 5-year survival of 78%. Conclusion: HAI therapy has a role in treating Hepatic metastases from CRC in both the resectable and unresectable setting.

  • treating primary liver cancer with Hepatic Arterial Infusion of floxuridine and dexamethasone does the addition of systemic bevacizumab improve results
    Oncology, 2011
    Co-Authors: Nancy E. Kemeny, Mithat Gonen, Yuman Fong, Alexandra N. Gewirtz, Michael I Dangelica, Lawrence H Schwartz, Adam C Yopp, David H Gultekin, Dana Haviland, Peter J Allen
    Abstract:

    Objectives: This study investigated the efficacy and safety of adding systemic (IV) bevacizumab (Bev) to Hepatic Arterial Infusion (HAI) with floxuridine (FUDR)/dexamethasone (Dex)

  • Unexpected increased biliary toxicity when systemic bevacizumab is added to Hepatic Arterial Infusion.
    Journal of Clinical Oncology, 2010
    Co-Authors: Derek G. Power, Yuman Fong, Marinela Capanu, Dina Patel, Alexandra N. Gewirtz, William R. Jarnagin, M. I. D'angelica, R. P. Dematteo, Nancy E. Kemeny
    Abstract:

    3559 Background: Hepatic Arterial Infusion (HAI) with floxuridine + dexamethasone can be added safely and effectively to systemic (SYS) oxaliplatin + irinotecan in unresectable colorectal cancer li...

  • Implanted Hepatic Arterial Infusion Pumps
    Cancer Journal, 2010
    Co-Authors: Margaret K. Callahan, Nancy E. Kemeny
    Abstract:

    : Globally, the number of colorectal carcinoma-related deaths totals close to 600,000 each year, with metastatic disease representing the major cause of morbidity and mortality. The liver is the most common site of metastasis for patients diagnosed with colorectal carcinoma. Although surgical resection is the mainstay for treatment with curative intent, this option is available to a minority of patients with metastatic disease. Hepatic Arterial Infusion chemotherapy was developed with the intention to focus treatment on a site of difficult to control metastatic disease. In this review, we aim to present the rationale for the development of Hepatic Arterial Infusion chemotherapy, the basic anatomic and pharmacological underpinnings of this treatment, the associated toxicities, and a brief survey of the expanding applications for this approach.

  • Hepatic Arterial Infusion after liver resection
    The New England Journal of Medicine, 2005
    Co-Authors: Nancy E. Kemeny, Mithat Gonen
    Abstract:

    To the Editor: In 1999, we reported on the results of a randomized study of adjuvant therapy after liver resection for metastatic colorectal cancer.1 One group of patients was treated with Hepatic Arterial Infusion with floxuridine and dexamethasone plus systemic fluorouracil, with or without leucovorin (combined therapy). The other group received systemic therapy alone, consisting of fluorouracil with or without leucovorin (monotherapy). We reported an increase in two-year survival for the combined-therapy group as compared with the group receiving monotherapy. We also reported a significant increase in the rate of survival free of Hepatic progression in the combined-therapy group. All . . .

Yuman Fong - One of the best experts on this subject based on the ideXlab platform.